Overview
- National surveillance data for the first 22 weeks of 2026 show more than 38,000 bronchiolitis cases and 563 hospitalizations attributed to respiratory syncytial virus.
- Argentina introduced maternal RSV vaccination in 2024 and this year added the long‑acting monoclonal nirsevimab for selected high‑risk infants such as those born prematurely or with congenital heart disease.
- Health experts and official reports say current measures leave a large protection gap because nirsevimab is limited to high‑risk groups and maternal antibodies typically protect infants for about six months.
- The province of Córdoba bought about 10,000 doses of nirsevimab to offer the antibody to babies born from January 1, 2026 who lack protection, with plans to give doses before maternity discharge and at provincial clinics.
- Clinicians warn that roughly 80% of severe RSV cases occur in previously healthy full‑term infants, making individual risk hard to predict and raising the prospect of greater strain on pediatric services if circulation continues to rise.